Beijer Els, Seldenrijk Kees, Eishi Yoshinobu, Uchida Keisuke, Damen Jan, Grutters Jan C, Veltkamp Marcel
Interstitial Lung Diseases Centre of Excellence, Dept of Pulmonology, St Antonius Hospital, Nieuwegein, The Netherlands.
Pathology DNA, Dept of Pathology, St Antonius Hospital, Nieuwegein, The Netherlands.
ERJ Open Res. 2021 Mar 22;7(1). doi: 10.1183/23120541.00486-2020. eCollection 2021 Jan.
Several studies demonstrated that may be involved in sarcoidosis pathogenesis. Presence of was found in granulomas of the majority of Japanese sarcoidosis patients. However, presence of in tissue has never been related to sarcoidosis phenotypes and clinical outcome. Therefore, the aims of our study were to demonstrate whether can be detected in granulomas of Dutch sarcoidosis patients and to investigate whether its presence is related to a clinical phenotype and/or course of disease. Sections of formalin-fixed paraffin-embedded tissue blocks of 76 sarcoidosis patients were examined by immunostaining with a specific monoclonal antibody (PAB antibody) using a Ventana BenchMark ULTRA. Clinical outcome status (COS) was determined and classified into two phenotype groups: A: resolved, minimal or persistent disease without treatment (COS 1-6) and B: persistent disease with need for treatment (COS 7-9). was detected in samples of 31 patients (41%) and located within granulomas in samples of 13 patients (17%). The frequency of detected in granulomas at diagnosis was significantly higher in patients with phenotype B compared to patients with phenotype A (29% 0%, p=0.021). Presence of in granulomas can be confirmed in Dutch sarcoidosis patients. It is intriguing that presence of in granulomas is more frequently found in patients with chronic disease requiring treatment. This adds to the rationale that a subgroup of sarcoidosis patients might benefit from antibiotic therapy.
多项研究表明,[具体物质]可能参与结节病的发病机制。在大多数日本结节病患者的肉芽肿中发现了[具体物质]的存在。然而,组织中[具体物质]的存在从未与结节病的表型和临床结局相关联。因此,我们研究的目的是证明在荷兰结节病患者的肉芽肿中是否能检测到[具体物质],并调查其存在是否与临床表型和/或疾病进程相关。使用Ventana BenchMark ULTRA,用一种特异性单克隆抗体(PAB抗体)对76例结节病患者的福尔马林固定石蜡包埋组织块切片进行免疫染色检查。确定临床结局状态(COS)并分为两个表型组:A组:疾病自行缓解、轻微或未经治疗持续存在(COS 1 - 6);B组:需要治疗的持续性疾病(COS 7 - 9)。在31例患者(41%)的样本中检测到了[具体物质],在13例患者(17%)的样本中位于肉芽肿内。与A表型患者相比,B表型患者在诊断时肉芽肿中检测到[具体物质]的频率显著更高(29%对0%,p = 0.021)。在荷兰结节病患者中可以证实肉芽肿中存在[具体物质]。有趣的是,在需要治疗的慢性病患者的肉芽肿中更频繁地发现[具体物质]的存在。这进一步支持了结节病患者的一个亚组可能从抗生素治疗中获益的理论依据。